Testing spinal fluid for gene changes in EGFR lung cancer that spread to the brain lining
Original title: CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase is listed. This is a small first study that collects and tests samples.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study checks if spinal fluid shows tumor gene changes that a blood test may miss.
Who this trial is for. This study is for people with non-small cell lung cancer that has an EGFR gene change and has spread to the lining of the brain and spinal cord. It tests spinal fluid and blood for tumor DNA, then compares what each one shows.
Where it stands. This study has not reported results. It is measuring whether the gene changes in spinal fluid differ from the gene changes in blood. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Gene changes help care teams pick which drugs may work. If spinal fluid gives a clearer picture of the cancer in the brain and spine, that could guide treatment choices later. Someone who fits this study might ask their care team about it.
What it doesn't mean: This does not mean there is a new treatment here. A trial is a test, not proven care. Being in one is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 19, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.